Bing Xu

Bing Xu


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2020 in Cell Biology International
Verified
Journal Article
Closed access
PDF file
JWJingyi Wen
Jingyi Wen
DWDan Wang
Dan Wang
LCLichun Cheng
Lichun Cheng
DWDi Wu
Di Wu
LQLulu Qiu
Lulu Qiu
HLHui-Yi Lv
Hui-Yi Lv

7 June 2022 in JMIR Medical Informatics
Verified
Journal Article
Open access
YWYan Wang
Yan Wang
JWJian Wang
Jian Wang
HLHuiyi Lu
Huiyi Lu
BXBing Xu
Bing Xu
YZYijia Zhang
Yijia Zhang
HLHongfei Lin
Hongfei Lin
Background: Event extraction is essential for natural language processing. In the biomedical field, the nested event phenomenon (event A as a participating role of event B) makes extracting this event more difficult than extracting a single event. Therefore, the performance of nested biomedical events is always underwhelming. In addition, previous works relied on a pipeline to build an event extraction model, which ignored the dependence between trigger recognition and event argument detection tasks and produced significant cascading errors.Objective: This study aims to design a unified framework to jointly train biomedical event triggers and arguments and improve the performance of extracting nested biomedical events.Methods: We proposed an end-to-end joint extraction model that considers the probability distribution of triggers to alleviate cascading errors. Moreover, we integrated the syntactic structure into an attention-based gate graph convolutional network to capture potential interrelations between triggers and related entities, which improved the performance of extracting nested biomedical events.Results: The experimental results demonstrated that our proposed method achieved the best F1 score on the multilevel event extraction biomedical event extraction corpus and achieved a favorable performance on the biomedical natural language processing shared task 2011 Genia event corpus.Conclusions: Our conditional probability joint extraction model is good at extracting nested biomedical events because of the joint extraction mechanism and the syntax graph structure. Moreover, as our model did not rely on external knowledge and specific feature engineering, it had a particular generalization performance.

1 November 2023 in Journal of Geriatric Cardiology
Verified
Journal Article
Open access
PDF file
JWJing-Yi Wen
Jing-Yi Wen
HPHui-Xi Peng
Hui-Xi Peng
DWDan Wang
Dan Wang
ZWZhi-Min Wen
Zhi-Min Wen
YLYu-Tong Liu
Yu-Tong Liu
BXBing Xu
Bing Xu
BACKGROUND Myocardial ischemia-reperfusion (I/R) is a serious and irreversible injury. Bone marrow-derived mesenchymal stem cells (MSCs) is considered to be a potential therapy for I/R injury due to the paracrine effects. High-mobility group box 1 (HMGB1) is a novel mediator in MSC and regulates the response of inflammation injury. Signal Transduction and Transcription Activator 3 (STAT3) is a critical transcription factor and important for release of paracrine factors. However, the relationship between HMGB1 and STAT3 in paracrine effect of MSC remains unknown. METHODS In vitro, hypoxia/reoxygenation injury model was established by AnaeroPack System and examined by Annexin V flow cytometry, CCK8 assay and morphology observation. Detection of apoptotic proteins and protein expression of HMGB1 and STAT3 by Western blot. RESULTS The conditioned medium of MSCs with or without LPS pretreatment was cocultured with H9C2 cells for 24 h before hypoxia treatment and MSC showed obvious cardiomyocytes protect role, as evidence by decreased apoptosis rate and improved cells viability, and LPS pretreated MSC exhibited better protect role than untreated MSC. However, such effect was abolished in HMGB1 deficiency group, silencing HMGB1 decreased the secretion of vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), insulin growth factor (IGF), cell viability, and the expression of STAT3. Furthermore, STAT3 silence attenuated the protective effect of LPS in MSC. CONCLUSIONS These findings suggested that LPS improved MSC-mediated cardiomyocytes protection by HMGB1/STAT3 signaling.

1 July 2022 in Canadian Journal of Physiology and Pharmacology
Verified
Journal Article
Closed access
DWDan Wang
Dan Wang
JWJing-Yi Wen
Jing-Yi Wen
DWDi Wu
Di Wu
ZYZi-Yue Ying
Zi-Yue Ying
ZWZhi-Min Wen
Zhi-Min Wen
BXBing Xu
Bing Xu
Mesenchymal stem cell-derived conditioned medium (MSC-CM) improves cardiac function, which is partly attributed to the released paracrine factors. Since such cardioprotection is moderate and transient, it is essential that MSC-CM's effective components are optimized to alleviate myocardial injury. To optimize MSC-CM, MSCs were treated with or without lipopolysaccharides (LPSs) for 48 h (serum-free), and the supernatant was collected. Then, LPS-CM (MSC stimulated by LPS) was further treated with LPS remover (LPS Re-CM) or was concentrated with a 10 kDa cutoff filter (10 kDa-CM). Enzyme-linked immunosorbent assay showed that all the pretreatments increased the levels of vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and insulin growth factor (IGF) except LPS Re-CM; 10 kDa-CM was superior to the other CMs. Cell Counting Kit-8 displayed that the viability of injured H9c2 cells was enhanced with the increase in the MSC-CM concentration. We also found that the 10 kDa-CM significantly alleviated H9c2 hypoxia/reoxygenation (H/R) injury, as evidenced by the increased Bcl-2/Bax ratio, and decreased the levels of lactate dehydrogenase and cardiac troponin. Transmission electron microscopy (TEM), TdT-mediated dUTP nick-end labelling (TUNEL), and hematoxylin and eosin staining (H&E) confirmed that 10 kDa-CM inhibited H/R-induced H9c2 morphological changes. Proteomic analysis identified 41 differentially expressed proteins in 10 kDa-CM, among which anti-inflammation, proangiogenesis, and antiapoptosis were related to cardiac protection. This study indicates that 10 kDa-CM protects H9c2 cardiomyocytes from H/R injury by preserving most of the protective factors, such as VEGF, HGF, and IGF, in MSC-CM.

13 June 2017 in Hereditary Cancer in Clinical Practice
Verified
Journal Article
Open access
PDF file
YJYan Jiang
Yan Jiang
CZChen-Yang Zhao
Chen-Yang Zhao
LCLi-Chun Cheng
Li-Chun Cheng
BXBing Xu
Bing Xu
HLHuiyi Lv
Huiyi Lv
Adenosine diphosphate (ADP)-ribosylation factor-like tumour suppressor gene 1(ARLTS1) might be associated with an increased risk of several types of familial cancers. However, previous studies have shown that cancer susceptibility is not completely consistent with ARLTS1 polymorphisms, and the precise mechanism remains unknown. Therefore, we conducted a meta-analysis of case-control studies by searching the PubMed, Embase, OVID, Science Direct and Chinese National Knowledge Infrastructure (CNKI) databases. In total, 12 studies met the inclusion criteria and were included in this meta-analysis. Statistical analyses were performed using STATA 11.0 software. Overall, the Cys148Arg T > C variant significantly increased cancer risk (CC vs. TT: OR = 1.27, 95% CI = 1.15–1.41, P < 0.05). The stratification indicated that the Cys148Arg variant is significantly associated with sporadic cancer (CC vs. TT: OR = 1.36, 95% CI = 1.18–1.55) and familial cancer (CC vs. TT: OR = 1.26, 95% CI = 1.12–1.43). Trp149Stop, Pro131Leu, Ser99Ser and Leu132Leu were not correlated with cancer susceptibility. Based on these results, we demonstrated that the ARLTS1 Cys148Arg polymorphism is associated with an increased risk of sporadic cancer and familial cancer, and there were no associations between the other four SNPs (i.e., Trp149Stop, Pro131Leu, Ser99Ser and Leu132Leu) and cancer risk.

9 May 2023
Verified
Preprint
Open access
BXBing Xu
Bing Xu
JWJing-Yi Wen
Jing-Yi Wen
HPHui-Xi Peng
Hui-Xi Peng
DWDan Wang
Dan Wang
ZWZhi-Min Wen
Zhi-Min Wen
CGCong Geng
Cong Geng
Myocardial ischemia-reperfusion (I/R) is a serious and irreversible injury. Bone marrow-derived mesenchymal stem cells (MSCs) is considered to be a potential therapy for I/R injury due to the paracrine effects. High-mobility group box 1 (HMGB1) is a novel mediator in MSC and regulates the response of inflammation injury. Signal Transduction and Transcription Activator 3 (STAT3) is a critical transcription factor and important for release of paracrine factors. However, the relationship between HMGB1 and STAT3 in paracrine effect of MSC remains unknown. In vitro , Hypoxia/Reoxygenation injury model was established by AnaeroPack System and examined by Annexin V flow cytometry, CCK8 assay and morphology observation. Detection of apoptotic proteins and protein expression of HMGB1 and STAT3 by Western blot. The conditioned medium of MSC with or without LPS pretreatment was cocultured with H9c2 cells for 24h before hypoxia treatment and MSC showed obvious cardiomyocytes protect role, as evidence by decreased apoptosis rate and improved cells viability, and LPS pretreated MSC exhibited better protect role than untreated MSC. However, such effect was abolished in HMGB1 deficiency group, silencing HMGB1 decreased the secretion of VEGF, HGF, IGF, cell viability, and the expression of STAT3. Furthermore, STAT3 silence attenuated the protective effect of LPS in MSC. Collectively, these findings suggested that LPS improved MSC-mediated cardiomyocytes protection by HMGB1/STAT3 signaling.